Singapore markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
273.73+4.08 (+1.51%)
At close: 04:00PM EDT
273.70 -0.03 (-0.01%)
After hours: 07:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close269.65
Open271.15
Bid273.77 x 800
Ask275.00 x 900
Day's range269.07 - 273.84
52-week range176.36 - 292.75
Volume1,479,123
Avg. volume1,652,447
Market cap70.317B
Beta (5Y monthly)0.55
PE ratio (TTM)28.89
EPS (TTM)9.48
Earnings date27 Jul 2022 - 01 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est291.93
  • Motley Fool

    3 Healthcare Stocks You Can Buy and Hold for the Next Decade

    You know that you can count on them for leadership in their market and earnings growth. Here, I'll focus on three companies that stand out for their strong market positions: a biotech company and a medical device company that each dominate their fields, and a pharmaceutical player on the way to winning in market share. Vertex Pharmaceuticals (NASDAQ: VRTX) is the worldwide leader in cystic fibrosis (CF) treatment.

  • Motley Fool

    Have $2,000? 2 Market Crash-Ready Stocks to Buy

    You may be spending a little more time than you'd like these days thinking about a future market crash. But instead of letting the recent stock-market decline scare us, we should let it help us: Let's use it as a reminder that market corrections and crashes will happen.

  • Motley Fool

    3 Stocks That Could Make You a Fortune Over the Next 10 Years

    Here's why they picked Exelixis (NASDAQ: EXEL), Moderna (NASDAQ: MRNA), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Exelixis): If you're looking to hit a home run with an investment, it's important to look for a balance of a modest valuation and promising growth. One underrated stock that possesses all these features is cancer-fighting company Exelixis, which has a market cap of around $5.4 billion.